| Business Summary | | RegeneRx
Biopharmaceuticals,
Inc.
is
a
pharmaceutical
research
and
development
company
focusing
on
the
development
of
products
to
treat
a
variety
of
human
diseases.
Historically,
the
Company's
primary
business
focus
was
the
commercialization
of
Thymosin
alpha
1
(T(alpha)1),
a
28-amino
acid
peptide
shown
to
regulate
the
immune
system
in
animal
models.
T(alpha)1
is
now
approved
for
the
treatment
of
hepatitis
b
and
c
and
as
an
immune
adjuvant
in
20
countries
outside
the
United
States,
and
is
in
registration
for
approval
in
several
more.
The
Company's
current
primary
business
focus
is
the
commercialization
of
Thymosin
beta
4,
a
43-amino
acid
peptide
(T(beta)4).
The
Company
is
concentrating
its
efforts
on
the
use
of
T(beta)4
for
the
treatment
of
injured
tissue
and
non-healing
wounds
to
enable
more
rapid
repair
and/or
tissue
regeneration. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | RegeneRx
Biopharmaceuticals
Inc.
is
a
pharmaceutical
research
and
development
company
focusing
on
the
development
of
products
to
treat
a
variety
of
human
diseases.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
before
extraordinary
item
totalled
$71
thousand
vs.
income
of
$458
thousand.
Revenues
reflect
the
the
lack
of
any
products.
Loss
reflects
a
decrease
in
realized
gains
on
the
sale
of
investments. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| Allan Goldstein, 63 Chairman,
Pres, CEO | $27K | Albert Rosenfeld, 79 Treasurer,
Sec., Director | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|